Share on StockTwits

Protalix BioTherapeutics (NYSE:PLX)‘s stock had its “hold” rating reaffirmed by Jefferies Group in a research note issued on Monday. They currently have a $3.50 target price on the stock, down from their previous target price of $4.25. Jefferies Group’s price objective suggests a potential upside of 14.01% from the company’s current price.

Shares of Protalix BioTherapeutics (NYSE:PLX) traded down 5.21% during mid-day trading on Monday, hitting $2.91. 209,099 shares of the company’s stock traded hands. Protalix BioTherapeutics has a 52 week low of $3.01 and a 52 week high of $5.60. The stock’s 50-day moving average is $3.43 and its 200-day moving average is $4.13. The company’s market cap is $269.7 million.

Protalix BioTherapeutics (NYSE:PLX) last announced its earnings results on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. Analysts expect that Protalix BioTherapeutics will post $-0.24 EPS for the current fiscal year.

Separately, analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.